Professional Financial Advisors’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

Professional Financial Advisors’s Portfolio BLPH Stock Details BLPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-500	Closed	-$2K	–	494
2021 Q3	$2K	Hold	500	–	–	﹤0.01%	384
2021 Q2	$3K	Hold	500	–	–	﹤0.01%	362
2021 Q1	$3K	Sell	500 -288	-37%	-$2.01K	﹤0.01%	320
2020 Q4	$5K	Hold	788	–	–	﹤0.01%	297
2020 Q3	$7K	Buy	+788	New	+$9.27K	0.01%	248

Other funds holding BLPH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Professional Financial Advisors's BLPH Position: Q4 2021 in Review

Professional Financial Advisors sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q4 2021, closing a stake of 500 shares — an estimated $2K sold.

Professional Financial Advisors first reported a position in BLPH in Q3 2020 and held it in 5 quarters. The position peaked at $7K in Q3 2020. 22 funds tracked by Wall St. Rank hold BLPH as of Q4 2021.

Professional Financial Advisors reported no remaining Bellerophon Therapeutics, Inc. position as of Q4 2021 after selling out during the quarter.
Professional Financial Advisors sold 500 Bellerophon Therapeutics, Inc. shares in Q4 2021, an estimated $2K.
Professional Financial Advisors first reported a position in Bellerophon Therapeutics, Inc. in Q3 2020 and held it in 5 quarters.
Professional Financial Advisors's Bellerophon Therapeutics, Inc. position peaked at $7K in Q3 2020.
22 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q4 2021.

Based on Professional Financial Advisors's 13F filing for Q4 2021, filed 18 Jan 2022.